This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.

This study has been completed.
Information provided by:
Sorlandet Hospital HF Identifier:
First received: September 6, 2005
Last updated: March 26, 2008
Last verified: March 2008
  • To evaluate if weekly psychological follow-up make opioid dependent patients in MMT able to accomplish 14 weeks treatment with Peginterferon alfa-2a (PEG-INF) and ribavirin to the same extent than non-opioid dependents.
  • To determine the efficacy of this anti-HCV treatment

Condition Intervention Phase
Opiate Dependence Hepatitis Drug: Ribavirin Drug: Pegylated Interferon Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a Methadone Maintenance Treated (MMT) Opioid Addicted Group.

Resource links provided by NLM:

Further study details as provided by Sorlandet Hospital HF:

Primary Outcome Measures:
  • - Percent of patients with sustained virological response, defined as undetectable HCV RNA 24 weeks after end of treatment [ Time Frame: 24 weeks after end of treatment ]

Secondary Outcome Measures:
  • Retention in treatment, compliance, psychological distress, measures of quality of life, perceived drug use control and urine toxicology [ Time Frame: 2, 4, 8, 14 and 24 weeks after study start ]

Estimated Enrollment: 10
Study Start Date: March 2006
Study Completion Date: January 2008
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Ribavirin
    800 mg pr. os daily, 400 mg morning and 400 mg evening (200 mg/tbl.) for 14 weeks
    Drug: Pegylated Interferon
    180 mikrogram in 0,5 ml solution s.c. once a week for 14 weeks
Detailed Description:

Chronic infection with the hepatitis C virus (HCV) is a health problem worldwide. In Norway, there are about 3000 patients participating in Methadone Maintenance Treatment(MMT) programs. A prevalence study at the MMT treatment unit in Kristiansand, showed that more than 90 % of 177 patients have been infected with hepatitis C.

A major problem with anti-HCV treatment for this group is the lack of compliance and retention in treatment. Further, due to the high incidence of psychological disorders in opioid dependent patients, this may also complicate anti-HCV treatment. Drug addicted in MMT treatments programs may find themselves excluded from Hepatitis C treatment.

Due to better treatment efficacy with the new PEG-INF's and encouraging reports from 14 weeks studies, it may be easier to motivate opioid dependents to fulfill treatment. Weekly psychological follow-up of these patients will further increase the possibility of opioid dependents in MMT to be able to complete anti-HCV treatment.

The aim of this study is to focus on this patients situation, and strengthen their possibility to have a real opportunity to get treatment. We therefore wish to make a pilot study to investigate the feasibility, efficacy and psycological side-effects of the treatment.


Ages Eligible for Study:   25 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Serologic evidence of hepatitis C infection, genotype 2 and 3
  • Normal or elevated serum ALT activity
  • In MMT-programme and with at least 6 months with satisfactory drug abuse control. That means no iv injections and no or minimal use of drugs.
  • Male and female patients

Exclusion Criteria:

  • Women with ongoing pregnancy or breast feeding
  • Untreated serious psychiatric disorders, particularly depression.
  • Serious drug abuse or alcohol abuse last 6 months
  • Intravenous drug abuse last 6 months
  • Hepatitis A, B or HIV infection
  • HCV genotype 1, 4, 5 and 6
  • Leucocytes < 3000 cells/mm3 at screening (neutrophil count <1500 cells/mm3)
  • Platelet count < 80 000 cells/mm3 at screening
  • Hb <11 g/dL in women or <12 g/dL in men at screening
  • Documented or presumed coronary artery disease or cerebrovascular disease
  • Thyroid dysfunction not adequately controlled
  • Epilepsy
  • Malignant disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00147784

Soerlandet Hospital HF
Kristiansand, Vest-Agder, Norway, 4604
Addiction Unit, Sorlandet Hospital
Kristiansand, Vest-Agder, Norway, N-4604
Sponsors and Collaborators
Sorlandet Hospital HF
Principal Investigator: Oistein Kristensen, MD Soerlandet Hospital HF
Principal Investigator: Oistein Kristensen, MD Addiction Unit, SSHF
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Oistein Kristensen, MD, Sorlandet Hospital HF Identifier: NCT00147784     History of Changes
Other Study ID Numbers: SSHF-70332
Protocol no 9772387
EudraCT no 2005-002869-37
Study First Received: September 6, 2005
Last Updated: March 26, 2008

Keywords provided by Sorlandet Hospital HF:
Chronical Hepatitis C treatment
Methadone Maintenance Treatment
Pegylated Interferon and Ribavirin
14 weeks treatment
Genotype 2 and 3

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Opioid-Related Disorders
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on September 21, 2017